Literature DB >> 1516246

The immunogenetic background of scleroderma--an overview.

C Black1, D Briggs, K Welsh.   

Abstract

Currently it may be stated that the MHC associations in scleroderma support the classification of disease subsets, but in no ethnic group is the overall association strong enough for clinical use. In different ethnic groups, the distribution of MHC alleles varies, as does the degree of linkage disequilibrium between alleles of the linked loci. This concept is even relevant to relatively close populations. Thus Whiteside noticed that, if those patients referred from more than 100 miles from the study centre were excluded, then the strength of the DR1 association increased. The environmental contribution to scleroderma is unknown, except in the case of toxin or solvent associated disease. Different causal environmental agents found in different global regions might result in separate MHC associations and hence explain the discrepancies noted above. There are indications that associations between specific subsets of SSc patients and genetic markers will assume greater importance both diagnostically and prognostically. The lung fibrosis group look prime candidates, for example. Genetic markers are also a useful means of relating chemically-induced SSc-like disorders to the classical disease. Vinyl chloride disease provides an example. There is much heterogeneity within the disease, in terms of extent of skin involvement, severity, and of organ involvement. It is clear that the different clinical subsets of scleroderma are characterized by different associated MHC alleles. There are also many cases of clinical overlap with related diseases, and certain of these diseases have a different HLA association, which could detract from the primary HLA type associated with SSc.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1516246     DOI: 10.1111/j.1365-2230.1992.tb00168.x

Source DB:  PubMed          Journal:  Clin Exp Dermatol        ISSN: 0307-6938            Impact factor:   3.470


  3 in total

1.  Exposure to chemicals and systemic sclerosis.

Authors:  L Czirják; Z Csiki; Z Nagy; E Tóth
Journal:  Ann Rheum Dis       Date:  1995-06       Impact factor: 19.103

2.  Expression of the human histocompatibility leukocyte antigen DR3 transgene reduces the severity of demyelination in a murine model of multiple sclerosis.

Authors:  K M Drescher; L T Nguyen; V Taneja; M J Coenen; J L Leibowitz; G Strauss; G J Hammerling; C S David; M Rodriguez
Journal:  J Clin Invest       Date:  1998-04-15       Impact factor: 14.808

3.  HLA-DQ polymorphism influences progression of demyelination and neurologic deficits in a viral model of multiple sclerosis.

Authors:  K D Pavelko; K M Drescher; D B McGavern; C S David; M Rodriguez
Journal:  Mol Cell Neurosci       Date:  2000-06       Impact factor: 4.314

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.